$TELA Bio (TELA.US)$ TELA Bio Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants TELA Bio has announced the pricing of a public offering comprising 12,000,000 shares of common stock at $2.25 per share and pre-funded warrants for 5,800,000 shares at $2.2499 per warrant. The offering is expected to generate $40 million in gross proceeds before expenses. The company has granted underwriters a 30-day option to purchase up to 2,670,000 additional shares. The offering, exp...
$TELA Bio (TELA.US)$ NEWS TELA Bio Announces U.S. Commercial Launch of Robotic-Compatible OviTex® IHR – Addressing the Need for a More Natural Repair in Inguinal Hernia Procedures TELA Bio, Inc. announces the U.S. commercial launch of OviTex IHR, a reinforced tissue matrix for inguinal hernia repair. The product offers trocar-compatibility for laparoscopic and robotic procedures, with three configurations available. OviTex has a strong clinical track record with low recurrence rates and high pati...
Despite TELA Bio's high revenue growth, its P/S ratio barely aligns with industry median, indicating public skepticism about future growth. Its current stock price could be attractive, yet it shows two risk signs.
TELA Bio Stock Forum
TELA Bio Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
TELA Bio has announced the pricing of a public offering comprising 12,000,000 shares of common stock at $2.25 per share and pre-funded warrants for 5,800,000 shares at $2.2499 per warrant. The offering is expected to generate $40 million in gross proceeds before expenses. The company has granted underwriters a 30-day option to purchase up to 2,670,000 additional shares. The offering, exp...
NEWS
TELA Bio Announces U.S. Commercial Launch of Robotic-Compatible OviTex® IHR – Addressing the Need for a More Natural Repair in Inguinal Hernia Procedures
TELA Bio, Inc. announces the U.S. commercial launch of OviTex IHR, a reinforced tissue matrix for inguinal hernia repair. The product offers trocar-compatibility for laparoscopic and robotic procedures, with three configurations available. OviTex has a strong clinical track record with low recurrence rates and high pati...
Beat revenue estimates and near miss on GAAP.
FDA approved surgical device
Buy this asap
No comment yet